NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
The purpose of NEI’s Translational Research program is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or c
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | PAR-26-073 |
| Posted date | 09/09/2025 |
| Expected number of awards | 5 |
| Who can apply | Other Eligible ApplicantsIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesFaith-based or Community-based OrganizationsRegional Organizations |
| Assistance Listing (CFDA) | 93.867 |
| Description | The purpose of NEI’s Translational Research program is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to three years and will support research that is in the final states of preclinical development with potential for near-term clinical develop |
| Agency contact | tony.gover@nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/360545 |